

Replace the fourth complete paragraph at page 16 with the following:

75
The peptide corresponding to the CDGF region of cadherin-12 (BR-cadherin; N-cadherin-2) having the amino acid sequence QPQPQQLATEPRENVIHL-PGQRSHFQRV (SEQ ID NO: 12), which has been synthesized by solid-phase synthesis as described under Example 1 for OB-CDGF, was tested for its survival-promoting effect on primary cultures of neurons from spinal ganglia of chicken embryos.

Replace the fourth complete paragraph at page 17 with the following:

76
The peptide corresponding to the CDGF region of cadherin-6 having the amino acid sequence TLSTPLSKRTSGFPAKKRALELSGNSKNELNRS (SEQ ID NO: 7) which has been synthesized by solid-phase synthesis as described under Example for OB-CDGF, was tested for its survival-promoting effect on primary cultures of neurons from spinal ganglia of chicken embryos. The test model has the design as described in Example 2.

IN THE CLAIMS

Rewrite claim 4 as follows.

4 (amended). A CDGF having the sequence

Cadherin-1 human (28-154) (SEQ ID NO: 1):

CHPGFDAESYTFTVPRRHLEGRVLGRVNFCTGRQRTAYFSLDTRFKVGTGDIVTKR-
PLRFHNPQIHFLVYAWDSTYRKFKSTKVTLNGHHHRPPPHQASVSGIQAELLTFPNSSP-
GLRRQKR

Cadherin-2 human (24-159) (SEQ ID NO: 2):

EASGEIALCKTGFPEDVYSAVLSKDVHEGQPLLNVFSNCNGKRKVQYESSEPADFKVD-
EDGMVYAVRSEPLSSEHAKFLIYAQDKETQEKWQKLSLKPTLTEESVKESAEVEEIVF-
PRQFSKHSGHLQRQKR

Cadherin-3 human (27-107) (SEQ ID NO: 3):

CP,AVFREAEVTLEAGGAEQEPGQALGKVFMGQEPALFSTDNDDFTVRNGETVQER-
RSLKERNPLKIFPSKRILRRHKR

Cadherin-4 human (21-169) (SEQ ID NO: 4):

HNEDLTTRETCKAGFSEDDYTALISQNILEGKLLQVKSSCVGTKGTQYETNSMDFKG-
ADGTVFATRELQVPSEQVAFTVTAWDSQTAEKWDAVLVAQTSSPHSGHKPQKGKKVVA-
LDPSPPPKDTLLPWPQHQNANGLRRRKR

Cadherin-5 human (26-47) (SEQ ID NO: 5):

AGANPAQRDTHSLLPTHRRQKR

Cadherin-6 human (19-53) (SEQ ID NO: 6):

TLSTPLSKRTSGEPAKKRALELSGNSKNELNRSKR

Cadherin-6 human (19-51) (SEQ ID NO: 7):

TLSTPLSKRTSGFPAKKRALELSGNSKNELNRS

Cadherin-8 human (SEQ ID NO: 8):

MLLDLWTPLILWITLPPCIYMAPMNQSQVLMMSGSPLELNSLGEEQRILNRSKR

Cadherin-B human (Cadherin-11) Precursor (23-53) (SEQ ID NO: 9):

FAPERRGHLRPSFHGHHEKGKEGQVLQRSKR

Cadherin-B human (Cadherin-11) Precursor (26-51) (SEQ ID NO: 10):
ERRGHLRPSFHGHHEKGKEGQVLQRS (OB-CDGF)

Cadherin-C human (Cadherin-12) -Brain-Cadherin Precursor (24- 54) (SEQ ID NO: 11):
QPQPQQTALATEPRENVHLPGQRSHFQRVKR

Cadherin-C human (Cadherin-12) -Brain-Cadherin Precursor (24- 52) (SEQ ID NO: 12):
QPQPQQTALATEPRENVHLPGQRSHFQRV

Cadherin-D human (Cadherin 13) (23-138) (SEQ ID NO: 13):
EDLDCTPGFQQKVFHINQPAEFIEDQSILNLTFSCKGNDKLRYEVSPPYFKVNSDGG-
LVALRNITAVGKTLFVHARTPHAEFDMAELVIVGGKDISLQDIFKFARTSPVPRQKRP-
SVLLLSLFLACL

Cadherin-F human (Cadherin 14) (22-60) (SEQ ID NO: 14):
VPGWRRPTTLYPWRRAPALSRVRRRAWVIPISVSENHKKR.

REMARKS

By the instant amendment, the specification and claims are amended to include sequence identifiers, as required in the Notice to Comply. Marked up versions of the amendments are attached, hereto.